OKYO Pharma CFO Keeren Shah's Stock Options and Common Stock Holdings

This Form 3 filing discloses the initial beneficial ownership of OKYO Pharma Ltd (OKYO) securities by Chief Financial Officer Keeren Shah. The filing reports direct ownership of 16,667 shares of common stock and extensive stock option grants. Shah holds multiple option tranches with exercise prices ranging from $1.46 to $2.13 per share, expiring between 2033 and 2035. The options have various vesting schedules with exercise dates spanning from 2024 to 2029. The largest option grants include 31,250 options at $1.50 exercise price expiring in 2034-2035, and 25,192-25,193 options at $2.13 exercise price expiring in 2033. This filing represents standard executive compensation disclosure for a newly appointed officer, showing significant equity-based incentive alignment with the company's long-term performance.